The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction
Launched by INSTITUT DE RECHERCHES INTERNATIONALES SERVIER · Aug 31, 2005
Trial Information
Current as of June 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Coronary artery disease
- • Left ventricular systolic dysfunction
- • Sinus rhythm: heart rate (HR) \>= 60 beats per minute (bpm)
- Exclusion Criteria:
- • Unstable cardiovascular condition
- • Severe congestive heart failure
About Institut De Recherches Internationales Servier
Institut de Recherches Internationales Servier is a leading independent international pharmaceutical company based in France, dedicated to advancing medical research and developing innovative therapeutic solutions. With a strong focus on areas such as cardiology, diabetes, oncology, and neuropsychiatry, Servier is committed to improving patient outcomes through rigorous clinical trials and collaboration with healthcare professionals worldwide. The organization emphasizes a patient-centric approach and invests significantly in research and development, striving to address unmet medical needs and enhance the quality of life for patients globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Kim Fox, MD
Study Chair
Royal Brompton National Heart and Lung Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials